Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Levy

Showing results (21-30 of 568) with videos related to

Pageof 57
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 26, 2021
Bright spotty lesions as an imaging marker for neuromyelitis optica spectrum disorderSara Salama, Michael Levy
The Medical Journal of Australia|April 10, 2021
Queensland's new Human Rights Act and the right to access health servicesMichael Levy, Daniel Mogg
Journal of Central Nervous System Disease|February 5, 2024
Advances in the long-term treatment of neuromyelitis optica spectrum disorderMonique Anderson, Michael Levy
Transfusion Medicine Reviews|September 24, 2022
New Treatment Perspectives for Acute Relapses in Neuromyelitis Optica Spectrum DisorderItay Lotan, Michael Levy
Harm Reduction Journal|May 6, 2009
Moving beyond non-engagement on regulated needle-syringe exchange programs in Australian prisonsDaniel Mogg, Michael Levy
Stroke|October 29, 2011
Pilot safety trial of deferiprone in 10 subjects with superficial siderosisMichael Levy, Rafael Llinas
Neurology Research International|February 25, 2012
Neuromyelitis optica: an antibody-mediated disorder of the central nervous systemJiwon Oh, Michael Levy
Vascular Medicine (London, England)|July 23, 2013
Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. Journal of the American Medical Association 2013; 309: 453-460Andrew K Kurklinsky, Michael Levy
Journal of Neuroimmunology|October 7, 2015
Favorable outcome of granulocyte colony-stimulating factor use in neuromyelitis optica patients presenting with agranulocytosis in the setting of rituximabMaureen A Mealy, Michael Levy
Immunotargets and Therapy|August 27, 2021
B-Cell Targeted Treatments for Neuromyelitis Optica Spectrum Disorder: A Focus on CD19 and CD20Michael Levy, Maureen A Mealy
Pageof 57

Showing results (21-30 of 568) with videos related to

Sort By:
Pageof 57
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 26, 2021
Bright spotty lesions as an imaging marker for neuromyelitis optica spectrum disorderSara Salama, Michael Levy
The Medical Journal of Australia|April 10, 2021
Queensland's new Human Rights Act and the right to access health servicesMichael Levy, Daniel Mogg
Journal of Central Nervous System Disease|February 5, 2024
Advances in the long-term treatment of neuromyelitis optica spectrum disorderMonique Anderson, Michael Levy
Transfusion Medicine Reviews|September 24, 2022
New Treatment Perspectives for Acute Relapses in Neuromyelitis Optica Spectrum DisorderItay Lotan, Michael Levy
Harm Reduction Journal|May 6, 2009
Moving beyond non-engagement on regulated needle-syringe exchange programs in Australian prisonsDaniel Mogg, Michael Levy
Stroke|October 29, 2011
Pilot safety trial of deferiprone in 10 subjects with superficial siderosisMichael Levy, Rafael Llinas
Neurology Research International|February 25, 2012
Neuromyelitis optica: an antibody-mediated disorder of the central nervous systemJiwon Oh, Michael Levy
Vascular Medicine (London, England)|July 23, 2013
Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. Journal of the American Medical Association 2013; 309: 453-460Andrew K Kurklinsky, Michael Levy
Journal of Neuroimmunology|October 7, 2015
Favorable outcome of granulocyte colony-stimulating factor use in neuromyelitis optica patients presenting with agranulocytosis in the setting of rituximabMaureen A Mealy, Michael Levy
Immunotargets and Therapy|August 27, 2021
B-Cell Targeted Treatments for Neuromyelitis Optica Spectrum Disorder: A Focus on CD19 and CD20Michael Levy, Maureen A Mealy
Pageof 57